Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors

Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors
Conditions: Peritoneal Carcinomatosis

Interventions: Drug: Mitomycin C (MMC); Device: Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC)

Sponsors: H. Lee Moffitt Cancer Center and Research Institute

Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

March 24, 2026Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments